Connection

Evangelos Terpos to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Evangelos Terpos has written about Antibodies, Monoclonal, Humanized.
Evangelos Terpos
Connection Strength
0.044
Antibodies, Monoclonal, Humanized
  1. Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
    View in: PubMed
    Score: 0.035
  2. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. 2017 Mar; 176(5):783-795.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.